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Aim: To study distribution and accumulation of liposomal form of doxorubicin in human breast cancer cells of MCF-7 line and 
Dox-resistant subline MCF-7/Dox. Methods: High performance liquid chromatography and laser confocal microscopy were used. 
Results: It has been shown that conventional form of doxorubicin was more efficiently delivered to the MCF-7 cells already after 
30 min of incubation amounting to its maximum concentration after 4 h. MCF-7/Dox cells are characterized by lower doxorubicin 
accumulation rate compared with parental cells. The quantity of accumulated liposomal form of doxorubicin is high in MCF-7 cells, 
and, what is important, Dox-resistant cells accumulated higher levels of liposomal form of doxorubicin than its conventional form. 
Conclusion: It has been shown that intracellular distribution and accumulation of liposomal forms of doxorubicin in parental and 
Dox-resistant MCF-7 cells differs from that of conventional doxorubicin. 
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Chemotherapy remains the standard treatment 
of both hematopoietic and solid tumors. Many cancers 
are characterized by an initial sensitivity to chemo-
therapy; however, acquired resistance to therapy in-
variably leads to patient relapse though the expansion 
of a multidrug-resistant population of cancer cells. 
The development of multiple drug resistance (MDR) 
remains the main problem in treatment of cancer pa-
tients [1]. Drug resistance develops toward practically 
each effective anticancer drug (ACD) with an involve-
ment of numerous mechanisms: reduced drug accu-
mulation; alterations in drug target; increased repair 
of drug-induced damage and inhibition of apoptotic 
signaling pathways [2–4].
An efficacy of anticancer therapy may be achieved 
by many ways, among which one could mention the 
generation of new forms of ACD, in particular liposomal 
ones. Preclinical studies have shown pharmacological 
benefits of liposomal forms of anthracycline, namely: 
pharmacokinetic patterns that are analogous to these 
for prolonged infusion of conventional anthracyclines, 
larger accumulation of the drug in tumor tissue and 
lower general toxicity compared to the conventional 
forms. The results of clinical trials have also shown 
more expressed cytotoxic action of liposomal forms 
of drug on cancer cells and decreased general tox-
icity of patient’s organism. It is very important, that 
drug resistance may be partially reversed upon the 
use of liposomal forms [5–7]. Liposomal systems for 
drug delivery may overcome an activity of transport 
MDR proteins even in highly resistant tumors. Lipo-
somes deliver the drug to the cytoplasm of the cancer 
cells by endocytosis, thus interaction with Pgp which 
is expressed on plasma membrane, is significantly 
decreased. Michieli et al. [8] have observed that treat-
ment of cell lines that overexpressed Pgp, by liposomal 
daunorubicin caused higher intracellular accumulation 
of the drug compared to the conventional form what 
led to 4–5 fold elevated cytotoxic effect. The mo-
lecular mechanisms of the binding and internalization 
of liposomal drugs are not fully understood. However, 
it is generally accepted that the majority of liposomes 
enter cells through endocytotic pathway. The mecha-
nism of this effect remains incompletely studied yet. 
It has been shown that the colon cancer cells and their 
resistant analogs do not differ by DNA damage degree 
upon the action of conventional form of doxorubicin 
(Dox) and its liposomal form (LipDox) [9]. The authors 
supposed that enhancement of the LipDox biological 
activity could be explained by existence of its other 
targets, not related to DNA. Experimental results sug-
gest that the enhancement of sensitivity of MDR cells 
using LipDox may be explained by an increase in cell 
drug incorporation and by an intracellular drug redis-
tribution [10–11]. Decreased accumulation of ACD and 
their increased efflux from the cell is a characteristic 
pattern of resistant cells even at low degree of the 
resistance [12]. Intracellular accumulation of ACDs 
is very important for evaluation of their cytotoxic ac-
tion. The studies of ACD accumulation, retention, 
distribution in the cell, and efflux from the cell is also 
important because such data may be useful for the 
development of therapeutic schemes.
MATERIALS AND METHODS
The study was carried ou t on human breast 
cancer cells of MCF-7 line and its resistant subline 
MCF-7/Dox. The resistant subline was produced 
by exposing MCF-7 cells in the presence of gradu-
ally increasing concentrations of Dox (“Ebeve”, 
Austria) at the range from 0.1 to 32 mg/ml [13]. The 
MCF-7/Dox cells were 8-fold more resistant to Dox 
than the parental cells.
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Quantitative evaluation of LipDox and Dox accu-
mulation by MCF-7 and MCF-7/Dох cells has been 
performed by the method of high performance liquid 
chromatography (HPLC). The cells were cultured for 
30 min, 1, 4 h in ISCOW culture medium with mentioned 
preparations at IC30 concentrations (that was equal 
to 2 and 4 μg/ml for parental and resistant cell lines, 
respectively). Then the cells were washed twice and 
were incubated for 24 h at Dox-free culture medium. 
Then incubation culture medium was collected, 
filtered through 0.2 μm filter and analyzed for LipDox 
and Dox content with the use of liquid chromatograph 
Agilent Technology 1200 (Germany) with diode array 
detector at wave length of 235 nm and fluorometric 
detector. Excitation wavelength (Ех=460), emission 
wavelength (Еm= 550). Column Zorbax SB-C8 Stable 
Bond Analytical 4, 6 x 250 mm 5-Micron was used. 
Flow rate of eluent (acetonitrile and buffer solution with 
рН 2.05) was 1 ml/min, column temperature was 30 °С, 
and gradient regimen for 15 min was applied. At least 
5 chromatograms per each sample were obtained. 
Calculation of the concentrations were performed 
by the method of absolute standard — by area of pike 
for standard Dox solution prepared with the use of Dox 
substance. As the control, culture medium of cells 
grown without Dox addition or Dox/acetonitril solution 
were used.
Determination of LipDox and Dox intracellular dis-
tribution was carried out by laser confocal microscopy. 
The cells were seeded on coverslips overnight and 
then cultured with Dox or LipDox as described above, 
washed in physiologic solution and fixed in 4% para-
formaldehyde solution for 20 min at 4 °С. Next, the 
cells were washed and placed in Faramount Aqueous 
Mounting Medium (DakoСytomation, Denmark). The 
preparations were examined with the use of laser 
confocal microscope LSM 510 META (CARL ZEISS, 
Germany) at excitation wave length of 540 nm and 
emission wave length of 590 nm.
RESULTS AND DISCUSSION
Quantitative evaluation of LipDox and Dox ac-
cumulation by the cells of MCF-7 and MCF-7/Dох 
lines. With the use of HPLC we have performed the 
study of LipDox and Dox accumulation in parental 
MСF-7 cells and in resistant MCF-7/Dox subline. It has 
been shown that after 30 min incubation of the cells 
with LipDox or Dox the latest is accumulated in MCF-
7/Dox cells in 3.7 times higher than Dox (37% versus 
10%), while MCF-7 cells accumulated larger amounts 
of Dox compared with its liposomal form (Table 1). 
Table 1. Kinetics of Dox and LipDox accumulation (%) in MCF-7 and MCF-7/
Dox cells
Incubation period
Cell line 30 min 1 h 4 hDox LipDox Dox LipDox Dox LipDox
MCF-7 46.66 ± 
0.33
34 ± 
0.57
55.66 ± 
0.88
70 ± 
1.15
64.66 ± 
0.88
82 ± 
1.73
MCF-7/Dox 10.66 ± 
0.66
36.66 ± 
0.66
34.66 ± 
0.33
44 ± 
1.15
27.6 ± 
1.45 
59.33 ± 
0.66
After 1 h incubation with the drugs, in the cells 
of parental line LipDox accumulation was higher than 
that of Dox (70% versus 56%). In resistant cells the 
level of LipDox accumulation was unaltered (45%), 
while Dox concentration elevated up to 35%. Accu-
mulation levels of Dox and LipDox at this time period 
could be related to different ways of cell penetration: 
by direct diffusion (mostly characteristic for Dox), 
or by endocytosis for liposomal form [14–17]. 
After 4 h of incubation in both cell lines maximal 
accumulation of the drugs has been registered: 
for LipDox in MCF-7/Dox subline up to 60%, and 
in MCF-7 cells — up to 83%, while for Dox these values 
yielded 28% and 65% for parental and resistant cells 
respectively; this fact pointed at increase efflux of the 
drug from the cells with resistant phenotype (Fig. 1).
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Fig. 1. Chromatographic analysis of doxorubicin content in cell 
culture medium during 4 h: a) MCF-7/Dox cells treated with Dox; 
b) MCF-7 cells treated with Dox; c) MCF-7/Dox cells treated with 
LipDox; d) MCF-7 cells treated with LipDoх
Maximal accumulation of the drugs in 4 h incuba-
tion period has been supported by determination 
of their concentration after 5 h of the cells incubation 
with LipDox and Dox. It have been shown the decrease 
of conventional forms of the drugs in parental and re-
sistant cells; however, LipDox content remained high 
enough even in MCF-7/Dox cells. 
At 4-h long incubation of the cells with the drugs 
and the following 24-h incubation with Dox-free cul-
ture medium, the Dox content in the cells sharply de-
creased and could not be detected by HPLC contrary 
to LipDox which efflux from cells occurred more slowly. 
So, the study has revealed that Dox accumulates 
in MCF-7 cells at large amounts just in 30 min of in-
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cubation, and its concentration in the cells reaches its 
maximum in 4 h. The resistant cells accumulated much 
lower amounts of Dox. In regard to LipDox, its quantity 
is high enough in sensitive cells, and is much higher 
in resistant MCF-7/Dox cells compared to conventional 
form of the drug. 
Determination of LipDox and Dox intracel-
lular distribution in MCF-7 and MCF-7/Dох cells. 
Intracellular drug accumulation is a complex process 
including drug uptake into the cell, retention and dis-
tribution in the cell, and efflux from the cell [18, 19]. 
Intracellular accumulation of ACDs is an important 
parameter for evaluation of their cytotoxic action. 
The use of laser confocal microscopy for determina-
tion of intracellular distribution of ACDs is beneficial 
compared to fluorescent microscopy due to higher 
resolution capacity and elimination of epifluorescence. 
It is known that doxorubicin is able to self fluorescence, 
what allows determining its distribution in cells without 
additional stainers. Confocal cell images were used 
to determine intracellular LipDox and Dox localization 
and accumulation in MCF-7 and MCF-7/Dox sublines 
after incubation with drugs for 30 min, 1 h, 4 h, and 
then incubated in Dox-free medium for additional 24 h. 
There are clearly determined three types of APC 
distribution: nuclear, cytoplasmic and mixed. The 
first one was presented by fluorescence localized 
in nucleus, having its shape and size. The second type 
looks like diffuse fluorescence of cytoplasm, without 
fluorescence in nuclei. The mixed type was mostly 
characteristic for the cells studied by us at certain time 
periods, and fluorescence was detected both in cell 
nucleus and cytoplasm. 
Already after 30 min incubation of parental 
MCF-7 cells with Dox we have registered Dox fluo-
rescence predominantly in nuclei, with homogenous 
type of fluorescence in all area (Fig. 2, а). At the same 
time in resistant MCF-7/Dox cells fluorescence was 
observed in the cytoplasm with higher fluorescence 
intensity in the perinuclear region (Fig. 2, e). 
After 1 h of incubation Dox accumulated in the nu-
clei of large majority of the MCF-7 cells, fluorescence 
became more intense, especially at periphery of the 
nucleus (Fig. 2, b). Fluorescence of Dox in MCF-7/Dох 
cells during 1 h incubation period was mostly observed 
in the perinuclear region of cytoplasm and in the nuclei 
(Fig. 2, f). Fluorescence intensity increased in first 
30 min and remained stable for 1 h.
The study has shown that after 4 h incubation 
with Dох fluorescence still had nuclear localization 
but its intensity decreased, and one could observe 
single inclusions with intense fluorescence in the cell 
cytoplasm located near plasma membrane (Fig. 2, c), 
possibly, exosomes for removal of drug metabolites 
from the cells. In resistant MCF-7/Dox cells intense 
fluorescence of the drugs was observed in perinuclear 
region as well as diffuse or point-like patterns in cy-
toplasm and in the nuclei (Fig. 2, g). MCF-7/Dox cells 
differed from parental MCF-7 cells by the presence 
of significantly lower level of fluorescence intensity. 
Cultivation of the cells with the drugs for 4 h and with 
the next incubation in doxorubicin-free medium has dem-
onstrated that after 24 h weak Dox fluorescence could 
be detected only in single cells of parental MCF-7 cells, 
but none — in resistant cell line (Fig. 2, d; Fig. 2, h).
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Fig. 2. In vitro confocal images of subcellular Dox fluorescence 
distribution in parental MCF-7 cells (a–d) and resistance MCF-7/
Dox cells (e–h): a–d — Dox fluorescence predominantly in nuclei; 
e–h — Dox fluorescence observed in perinuclear region of cyto-
plasm, in nuclei and as separate cytoplasmic vesicles
So, one may conclude that Dox fluorescence 
is registered predominantly in the nuclei of MCF-7 cells, 
while in resistant cells Dox is mostly accumulated 
in cell cytoplasm, with the highest intensity in peri-
nuclear region or in point-like cytoplasmic inclusion. 
Fluorescence in the nuclei is registered only after 
1 h of incubation. Lower Dox fluorescence is caused 
by functioning of the system for reverse ACD transport 
from resistant cells due to Pgp expression. 
Intracellular distribution of ACD is modified 
in a large number of drug resistant cell lines [18, 19]. 
Predominantly diffuse localization of Dox in the cyto-
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plasm or perinuclear region of the resistant cells could 
be explained, firstly, by significant Pgp expression 
not only on plasma membrane, but also on nuclear 
membrane [20]. Secondly, recent studies suggests 
that Pgp has expressed also on membranes of Golgi 
apparatus, where Pgp promotes ACD accumulation 
inside this organelle with its following removal from 
the vesicles separated from Golgi complex [21]. The 
location of well developed 2–3 loci Golgi complex 
in perinuclear space of resistant cells demonstrated 
by us using electron microscopy, supports the pos-
sibility of Dox accumulation in structural elements 
of this organelle [22]. 
When MCF-7 cells were treated with LipDox 
there have been detected the changes of patterns 
of fluorescence (Fig. 3, a–d; Fig. 3, e–h). After 30 min 
treatment LipDox is distributed by all cytoplasm area 
of MCF-7 and MCF-7/Dox cells, along with generation 
of large regions of fluorescence in perinuclear region 
of cytoplasm of MCF-7 cells (Fig. 3, а), or characteris-
tic diffuse staining of cytoplasm of resistant cells with 
small point-like inclusions (Fig. 3, e). Local accumu-
lation of LipDox may be related to endocytosis of the 
drug in the cells in addition to its diffusion. It’s neces-
sary to note that fluorescence level of LipDox-treated 
cells is lower than that of Dox-treated cells and was 
detected in lower number of the cells, what could point 
on slower entrance of LipDox in cells compared to Dox. 
After 1 h incubation with LipDox the latest could 
be detected in the cytoplasm and nuclei of low percent 
of parental cells (Fig. 3, b) or as diffuse fluorescence 
in cytoplasm of MCF-7/Dox cells (Fig. 3, f). It’s neces-
sary to note that in MCF-7/Dox cells the fluorescence 
degree is increased, and there appeared large fluores-
cent zones in perinuclear space. 
If the cells were cultivated with the drug for 4 h, 
there has been shown a weak fluorescence in nuclei 
of MCF-7 cells (Fig. 3, c), while high fluorescence 
intensity in MCF-7/Dox cells was located in nuclei 
as discrete regions, or it formed local clusters in cy-
toplasm (Fig. 3, g). Such patterns of fluorescence 
may respond to vacuoles and endosomes that were 
observed at large quantities during electron micros-
copy study. The presence of such vesicles may serve 
as an evidence of enhanced membrane traffic in drug 
resistant cells. 
Further cultivation of the cells without the drugs has 
shown that after 24 h very weak diffuse fluorescence 
could be detected in parental MCF-7 cells (Fig. 3, d), 
while in resistant cells fluorescence could be observed 
not only in cytoplasm, but also in nuclei as diffuse 
or point-like patterns of fluorescence (Fig. 3, h). 
In conclusion, our study has demonstrated that 
accumulation and intracellular distribution of lipo-
somal forms of doxorubicin differs in parental and 
Dox-resistant MCF-7 cells from that of its conventional 
form. It has been shown that liposomal form of drug 
accumulates at higher degree and in more prolonged 
fashion in resistant MCF-7/Dox cells compared to con-
ventional Dox. 
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Fig. 3. In vitro confocal images of subcellular LipDox fluores-
cence distribution in parental MCF-7 cells (a–d) and resistance 
MCF-7/Dox cells (e-h): a–d — Dox fluorescence in cytoplasms 
and after 4 hour in nuclei (c); e–h — diffuse and point-like fluores-
cence localization of Dox in cytoplasm and in perinuclear region
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